These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 26574848)

  • 21. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
    Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
    BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
    Zhang X; Wang C; Shen D
    Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome.
    Alam NA; Barclay E; Rowan AJ; Tyrer JP; Calonje E; Manek S; Kelsell D; Leigh I; Olpin S; Tomlinson IP
    Arch Dermatol; 2005 Feb; 141(2):199-206. PubMed ID: 15724016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report.
    Garg K; Tickoo SK; Soslow RA; Reuter VE
    Am J Surg Pathol; 2011 Aug; 35(8):1235-7. PubMed ID: 21753700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.
    Lehtonen R; Kiuru M; Vanharanta S; Sjöberg J; Aaltonen LM; Aittomäki K; Arola J; Butzow R; Eng C; Husgafvel-Pursiainen K; Isola J; Järvinen H; Koivisto P; Mecklin JP; Peltomäki P; Salovaara R; Wasenius VM; Karhu A; Launonen V; Nupponen NN; Aaltonen LA
    Am J Pathol; 2004 Jan; 164(1):17-22. PubMed ID: 14695314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
    Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
    Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological and molecular characteristics of fumarate hydratase-deficient uterine smooth muscle tumors: a single-center study of 52 cases.
    Li H; Yang W; Tu X; Yu L; Huang D; Cheng Y; Chang B; Tang S; Ge H; Bao L; Zhou X; Bi R
    Hum Pathol; 2022 Aug; 126():136-145. PubMed ID: 35659509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benign metastasizing fumarate hydratase (FH)-deficient uterine leiomyomas: clinicopathological and molecular study with first documentation of multi-organ metastases.
    Yin X; Wei X; Al Shamsi R; Ali FS; Al Kindi F; Zhang X; Liang J; Pan X; Al Masqari M; Zheng L; Zhou Q; Agaimy A; Chen N
    Virchows Arch; 2024 Aug; 485(2):223-231. PubMed ID: 38642139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas.
    Ahvenainen T; Kaukomaa J; Kämpjärvi K; Uimari O; Ahtikoski A; Mäkinen N; Heikinheimo O; Aaltonen LA; Karhu A; Bützow R; Vahteristo P
    Am J Surg Pathol; 2022 Apr; 46(4):537-546. PubMed ID: 34678832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer.
    Alam NA; Olpin S; Leigh IM
    Br J Dermatol; 2005 Jul; 153(1):11-7. PubMed ID: 16029320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
    Alam NA; Rowan AJ; Wortham NC; Pollard PJ; Mitchell M; Tyrer JP; Barclay E; Calonje E; Manek S; Adams SJ; Bowers PW; Burrows NP; Charles-Holmes R; Cook LJ; Daly BM; Ford GP; Fuller LC; Hadfield-Jones SE; Hardwick N; Highet AS; Keefe M; MacDonald-Hull SP; Potts ED; Crone M; Wilkinson S; Camacho-Martinez F; Jablonska S; Ratnavel R; MacDonald A; Mann RJ; Grice K; Guillet G; Lewis-Jones MS; McGrath H; Seukeran DC; Morrison PJ; Fleming S; Rahman S; Kelsell D; Leigh I; Olpin S; Tomlinson IP
    Hum Mol Genet; 2003 Jun; 12(11):1241-52. PubMed ID: 12761039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
    Bhola PT; Gilpin C; Smith A; Graham GE
    Fam Cancer; 2018 Oct; 17(4):615-620. PubMed ID: 29423582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas.
    Barker KT; Spendlove HE; Banu NS; Bridge JA; Fisher C; Shipley J; Garrett M; Manyonda I; Houlston RS
    Cancer Lett; 2006 Apr; 235(1):136-40. PubMed ID: 15949892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata.
    Shi Y; Xu Y; Wang C; Chen Y; Ren X; Kang Y; Wang C
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36981015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
    Bayley JP; Launonen V; Tomlinson IP
    BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
    Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
    Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry.
    Reyes C; Karamurzin Y; Frizzell N; Garg K; Nonaka D; Chen YB; Soslow RA
    Mod Pathol; 2014 Jul; 27(7):1020-7. PubMed ID: 24309325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas.
    Barker KT; Bevan S; Wang R; Lu YJ; Flanagan AM; Bridge JA; Fisher C; Finlayson CJ; Shipley J; Houlston RS
    Br J Cancer; 2002 Aug; 87(4):446-8. PubMed ID: 12177782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fumarate hydratase immunohistochemical staining may help to identify patients with multiple cutaneous and uterine leiomyomatosis (MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome.
    Llamas-Velasco M; Requena L; Kutzner H; Schärer L; Rütten A; Hantschke M; Paredes BE; Mentzel T
    J Cutan Pathol; 2014 Nov; 41(11):859-65. PubMed ID: 25292446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and molecular genetic aspects of hereditary multiple cutaneous leiomyomatosis.
    Badeloe S; Frank J
    Eur J Dermatol; 2009; 19(6):545-51. PubMed ID: 19939761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.